|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In addition, PSG-1 decreased the tumor weight and increased the apoptosis rate and caspase-3 and caspase-9 activities of tumor derived from the C3H/HeN mice.
|
25549720 |
2015 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In contrast, administration of PSG-1 markedly suppressed tumor growth in CT26 tumor-bearing mice.
|
24506418 |
2014 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together, these data provide evidence that PSG-1 can be employed as an alternative dietary supplement to ameliorate T1DM.
|
31616874 |
2019 |
|
SVEINSSON CHORIORETINAL ATROPHY
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that PSG-1 pretreatment effectively reduced the levels of malondialdehyde (MDA), but increased the activity of catalase (CAT), superoxide dismutase (SOD), glutathione (GSH) and the total glutathione (T-GSH), and significantly reduced oxidative stress in AA treated rats.
|
31464322 |
2019 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to the 8<sup>th</sup>-edition of the tumor-nodes-metastasis-classification localized prostate cancer (PCa) can be divided into two categories (cT1,cT2), two stages (SI,SII), and, by incorporating prostate-specific-antigen (PSA) and WHO-grade (Gleason-Score), into prognostic stage groups (PSG I,IIA,IIB,IIC,III).
|
30176542 |
2018 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
According to the 8<sup>th</sup>-edition of the tumor-nodes-metastasis-classification localized prostate cancer (PCa) can be divided into two categories (cT1,cT2), two stages (SI,SII), and, by incorporating prostate-specific-antigen (PSA) and WHO-grade (Gleason-Score), into prognostic stage groups (PSG I,IIA,IIB,IIC,III).
|
30176542 |
2018 |
|
Mitochondrial Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, administration of PSG-1 suppressed DOX-induced mitochondrial disorders, which was evidenced by reducing reactive oxygen species, elevating mitochondrial membrane potential and inhibiting the opening of mitochondrial permeability transition pore.
|
30287039 |
2018 |
|
Endothelial dysfunction
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Taken together, these findings suggested that PSG-1 could be as a promising adjuvant against endothelial dysfunction through ameliorating oxidative stress and apoptosis.
|
28108410 |
2017 |
|
Immunosuppression
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, these findings have demonstrated that PSG-1 may ameliorate CTX-induced immunosuppression through reducing apoptosis and oxidative damage in immunological system.
|
27913287 |
2017 |
|
Down Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
The efficiency of six maternal serum markers for Down's syndrome (DS), alpha fetoprotein (AFP), human chorionic gonadotropin (hCG), free beta-hCG, pregnancy-associated plasma protein-A (PAPP-A), the proform of eosinophil major basic protein (ProMBP), pregnancy-specific-beta-1-glycoprotein (SP(1)), and combinations thereof, was examined.
|
15032969 |
2004 |
|
Complete Trisomy 21 Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
The efficiency of six maternal serum markers for Down's syndrome (DS), alpha fetoprotein (AFP), human chorionic gonadotropin (hCG), free beta-hCG, pregnancy-associated plasma protein-A (PAPP-A), the proform of eosinophil major basic protein (ProMBP), pregnancy-specific-beta-1-glycoprotein (SP(1)), and combinations thereof, was examined.
|
15032969 |
2004 |
|
Parkinsonian Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
This kindred (PSG-1) is included in the 'frontotemporal dementias and Parkinsonism linked to chromosome 17' group along with kindreds affected by apparently different forms of atypical dementias.
|
10202939 |
1999 |
|
Frontotemporal dementia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This kindred (PSG-1) is included in the 'frontotemporal dementias and Parkinsonism linked to chromosome 17' group along with kindreds affected by apparently different forms of atypical dementias.
|
10202939 |
1999 |
|
Hydatidiform Mole
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Linkage of two human pregnancy-specific beta 1-glycoprotein genes: one is associated with hydatidiform mole.
|
2377620 |
1990 |
|
HYDATIDIFORM MOLE, RECURRENT, 1
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Linkage of two human pregnancy-specific beta 1-glycoprotein genes: one is associated with hydatidiform mole.
|
2377620 |
1990 |
|
Acute Promyelocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A pregnancy-specific beta 1-glycoprotein, a CEA gene family member, expressed in a human promyelocytic leukemia cell line, HL-60: structures of protein, mRNA and gene.
|
2789512 |
1989 |
|
Promyelocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A pregnancy-specific beta 1-glycoprotein, a CEA gene family member, expressed in a human promyelocytic leukemia cell line, HL-60: structures of protein, mRNA and gene.
|
2789512 |
1989 |
|
cervical cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
Sodium butyrate produces concordant expression of "early placental" alkaline phosphatase, pregnancy-specific beta 1-glycoprotein and human chronic gonadotropin beta-subunit in a newly established uterine cervical cancer cell line (SKG-IIIa).
|
6604031 |
1983 |